Abstract | INTRODUCTION: METHODS: Patients with KRAS, NRAS, and BRAF wt mCRC with prior 5-FU, irinotecan, oxaliplatin, +/- bevacizumab and no prior anti-EGFR therapy were treated with trametinib 1.5 mg oral daily and panitumumab 4.8 mg/kg IV every 2 weeks. Primary endpoint was clinical benefit rate (CB; CR, PR, or SD ≥24 weeks) by RECIST v1.1. A 2-stage minimax design was used. Serial plasma circulating free DNA ( cfDNA) was collected and profiled using Oncomine Lung cfDNA assay. RESULTS: Fourteen patients were enrolled from November 2015 to April 2019. CB rate was 38% (5/13) and median progression free survival (PFS) was 4.4 months (95% CI, 2.9-7.1). Confirmed overall response rate was 38% (5/13). Treatment-related AE (trAE) included acneiform rash (85%), diarrhea (62%), maculopapular rash (54%), mucositis (46%), and others. Dose modifications and interruptions of trametinib occurred in 69% and panitumumab in 54% of patients. The trial did not progress to stage II accrual due to tolerability and short duration of response. RAS or BRAF mutations cfDNA were detected in 3/13 patients (23%) before radiographic disease progression. CONCLUSION:
|
Authors | Kanan Alshammari, Kyaw L Aung, Tong Zhang, Albiruni R A Razak, Stefano Serra, Tracy Stockley, Lisa Wang, Jessica Nguyen, Anna Spreafico, Aaron R Hansen, Dave Zwir, Lillian L Siu, Philippe L Bedard |
Journal | Clinical colorectal cancer
(Clin Colorectal Cancer)
Vol. 20
Issue 4
Pg. 334-341
(12 2021)
ISSN: 1938-0674 [Electronic] United States |
PMID | 34417144
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2021. Published by Elsevier Inc. |
Chemical References |
- Pyridones
- Pyrimidinones
- trametinib
- Panitumumab
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects)
- Colorectal Neoplasms
(drug therapy, genetics)
- Humans
- Panitumumab
(therapeutic use)
- Pyridones
- Pyrimidinones
(adverse effects)
|